Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | PRKACG | P22612 | 2/20 | 0.38 |
| ▸ | PRKACB | P22694 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565956 | 0.78 | PRKACA (0.36) | HTTPRKACAPRKACGPRKACBMEN1 | |
| SCHEMBL29447301 | 0.78 | PRKACA (0.36) | HTTPRKACAPRKACGPRKACBMEN1 | |
| SCHEMBL27427296 | 0.78 | PRKACA (0.46) | PRKACAPRKACGPRKACBMEN1KMT2A | |
| SCHEMBL27886224 | 0.77 | MYC (0.40) | MEN1KMT2ANPSR1ADORA2AADORA1 | |
| SCHEMBL7912645 | 0.75 | PRKACA (0.38) | PRKACAPRKACGPRKACBMEN1KMT2A | |
| SCHEMBL31437529 | 0.75 | KCNMA1 (0.36) | HTTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL31622333 | 0.75 | LRRK2 (0.40) | HTTPRKACAPRKACGPRKACBMEN1 | |
| SCHEMBL22980341 | 0.75 | PRKACA (0.38) | HTTPRKACAPRKACGPRKACBMEN1 | |
| SCHEMBL15741185 | 0.75 | LRRK2 (0.40) | HTTPRKACAPRKACGPRKACBMEN1 | |
| SCHEMBL1261198 | 0.75 | NOS2 (0.54) | HTTPRKACAPRKACGPRKACBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4558498-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546608-A | Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240409531-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024183806-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2024-09-12 | — | — | WO | disclosed |
| EP-4416134-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240043402-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2024017857-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-4259608-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023064196-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2220083-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009062676-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | ACIN1, CD4, NFATC1 | HTT 3414/4885PRKACA 2674/4885PRKACG 2309/4885 |
| US-20240409531-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | NFATC1, ACIN1, GZMB | HTT 4024/4885PRKACA 3633/4885PRKACG 3583/4885 |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | HTT 1862/4885PRKACA 3037/4885PRKACG 2547/4885 |
| US-20240043402-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, CD4, NFATC1 | HTT 3414/4885PRKACA 2674/4885PRKACG 2309/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | HTT 383/4885PRKACA 4442/4885PRKACG 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.